Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 1
1998 6
1999 1
2000 5
2001 12
2002 11
2003 11
2004 4
2005 10
2006 15
2007 14
2008 14
2009 19
2010 15
2011 13
2012 11
2013 11
2014 15
2015 15
2016 16
2017 14
2018 1
2019 4
2020 6
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

227 results
Results by year
Filters applied: . Clear all
Page 1
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized relapse rate over a period of 2 years. The study was not designed to test the superiority or noninferiority of BG-12 versus glatiramer
An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized rel …
Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.
Cheshmavar M, Mirmosayyeb O, Badihian N, Badihian S, Shaygannejad V. Cheshmavar M, et al. Acta Neurol Scand. 2021 Feb;143(2):178-187. doi: 10.1111/ane.13344. Epub 2020 Oct 27. Acta Neurol Scand. 2021. PMID: 32897569 Clinical Trial.
BACKGROUND: Treatment options for secondary progressive multiple sclerosis (SPMS) are limitedly investigated. We aimed to compare the efficacy of rituximab (RTX) and glatiramer acetate (GA) in SPMS patients. METHOD: This open, randomized clinical trial was conducted …
BACKGROUND: Treatment options for secondary progressive multiple sclerosis (SPMS) are limitedly investigated. We aimed to compare the effica …
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G, Freedman MS, Meca-Lallana JE, Vermersch P, Kim BJ, Parajeles A, Edwards KR, Gold R, Korideck H, Chavin J, Poole EM, Coyle PK. Comi G, et al. BMC Neurol. 2020 Oct 6;20(1):364. doi: 10.1186/s12883-020-01937-4. BMC Neurol. 2020. PMID: 33023488 Free PMC article. Clinical Trial.
RESULTS: Most frequently received prior DMTs at baseline were glatiramer acetate and interferon beta-1a across treatment groups. Teriflunomide 14 mg significantly reduced ARR versus placebo in the core period, regardless of prior treatment status. ...
RESULTS: Most frequently received prior DMTs at baseline were glatiramer acetate and interferon beta-1a across treatment group …
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Bovis F, Kalincik T, Lublin F, Cutter G, Malpas C, Horakova D, Havrdova EK, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Izquierdo G, Eichau S, Patti F, Terzi M, Grammond P, Bergamaschi R, Sola P, Ferraro D, Ozakbas S, Iuliano G, Boz C, Hupperts R, Grand'Maison F, Oreja-Guevara C, van Pesch V, Cartechini E, Petersen T, Altintas A, Soysal A, Ramo-Tello C, McCombe P, Turkoglu R, Butzkueven H, Wolinsky JS, Solaro C, Sormani MP. Bovis F, et al. Neurology. 2021 Jan 12;96(2):e214-e227. doi: 10.1212/WNL.0000000000010991. Epub 2020 Oct 6. Neurology. 2021. PMID: 33024022 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-beta-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. ...
OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-beta-1a), we appli …
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ. Gold R, et al. Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27207449 Free PMC article. Clinical Trial.
METHODS: In ENDORSE, patients randomized to DMF 240 mg twice (BID) or thrice daily (TID) in DEFINE/CONFIRM continued this dosage, and those initially randomized to placebo (PBO) or glatiramer acetate (GA) were re-randomized to DMF 240 mg BID or TID. ...
METHODS: In ENDORSE, patients randomized to DMF 240 mg twice (BID) or thrice daily (TID) in DEFINE/CONFIRM continued this dosage, and those …
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
METHODS: In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer. Eligible participants were randomly allocated in a 1:2:2 ra …
METHODS: In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting mult …
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F; Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group. Cohen J, et al. JAMA Neurol. 2015 Dec;72(12):1433-41. doi: 10.1001/jamaneurol.2015.2154. JAMA Neurol. 2015. PMID: 26458034 Clinical Trial.
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives. OBJECTIVE: To evaluate in the Glatiramer Acetate Clinical Trial to Assess Equivalence With Co …
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity …
Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
Salter A, Kowalec K, Fitzgerald KC, Cutter G, Marrie RA. Salter A, et al. Neurology. 2020 Aug 4;95(5):e446-e456. doi: 10.1212/WNL.0000000000010024. Epub 2020 Jun 17. Neurology. 2020. PMID: 32554770 Clinical Trial.
OBJECTIVE: To determine whether comorbidity is associated with clinical (relapses, disability worsening) and MRI outcomes in multiple sclerosis (MS) by conducting a secondary analysis of the CombiRx clinical trial. METHODS: CombiRx compared interferon beta-1a, glatiramer
OBJECTIVE: To determine whether comorbidity is associated with clinical (relapses, disability worsening) and MRI outcomes in multiple sclero …
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center. Wolinsky JS, et al. Mult Scler. 2001 Feb;7(1):33-41. doi: 10.1177/135245850100700107. Mult Scler. 2001. PMID: 11321192 Clinical Trial.
At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1,476 +/- 63 days, and 69 randomized to active treatment with glatiramer acetate (oGA) were on drug for 2,433 +/- 59 days. ...These …
At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1,476 …
The PROMiSe trial: baseline data review and progress report.
Wolinsky JS; PROMiSe Trial Study Group. Wolinsky JS, et al. Mult Scler. 2004 Jun;10 Suppl 1:S65-71; discussion S71-2. doi: 10.1177/135245850401000112. Mult Scler. 2004. PMID: 15218813 Review.
The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). ...
The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer ace
227 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page